Elevation Oncology, Inc. (ELEV)

Market Cap	21.63M
Revenue (ttm)	n/a
Net Income	-47.99M
EPS	-0.81
Shares Out	59.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,819,177
Open	0.3735
Previous Close	0.3729
Day's Range	0.3525 - 0.3794
52-Week Range	0.2210 - 3.0900
Beta	1.50
Analysts	Hold
Price Target	1.77 (+384.93%)
Earnings Date	Aug 5, 2025

About ELEV

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It’s lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: ELEV
• Website: https://elevationoncology.com

Analyst Summary

According to 6 analysts, the average rating for ELEV stock is "Hold." The 12-month stock price target is $1.77, which is an increase of 384.93% from the latest price.

Price Target

$1.77

(384.93% upside)

Analyst Consensus: Hold